Shares of Galectin Therapeutics (NASDAQ: GALT) are up more than 8% this morning on the company’s report of positive results from an exploratory, phase 2a clinical trial with GR-MD-02 in patients with moderate-to-severe plaque psoriasis. The research, which was done in partnership with San Antonio Military Medical Center, shows that GR-MD-02 achieved an average PASI (Psoriasis Area and Severity Index) reduction of over 50% in all patients that participated in the 24-week trial. The data also showed no serious adverse events, further demonstrating the safety and efficacy of this novel investigational drug in this patient population. The company will be presenting data at Maui Derm for Dermatologists on March 20-23, 2017, in Maui, Hawaii. “Moreover, the activity of GR-MD-02 in a human disease strongly associated with non-alcoholic steatohepatitis (NASH) and increased galectin-3 expression suggests that our lead compound may also show significant activity in NASH, which remains the company’s primary target,” president, chief medical officer and CEO Peter G. Traber, M.D. stated in the news release.
To view the full press release, visit: http://nnw.fm/mBz9G
About Galectin Therapeutics
Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the company’s unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.
About NetworkNewsBreak
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com.
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
